Fenwick Represents Dermira in its $287.5 Million Convertible Senior Notes Offering

Fenwick & West represented Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, in its offering of $287.5 million aggregate principal amount of 3.00% convertible senior notes due 2022. The notes were issued pursuant to an Indenture between Dermira and U.S. Bank National Association, as trustee, pursuant to Rule 144A under the Securities Act of 1933, as amended.

Leerink Partners LLC and Cowen and Company, LLC acted as joint book-running managers for the offering, and Mizuho Securities USA LLC and Needham & Company, LLC acted as co-managers for the offering. Evercore Group L.L.C. acted as Dermira's financial advisor for the offering.

The Fenwick transaction team was led by corporate partners Michael Brown, David Michaels and Doug Cogen, and included associates Katherine Duncan, Jennifer Hitchcock and Jeremy Kazzaz.